




The relative strengths and weaknesses of Zevra Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zevra Therapeutics INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Zevra Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 152% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	46,996
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,509
Liabilities, Non-Current	794
Other Assets	3,456
Other Compr. Net Income	0
Other Expenses	-43
Other Liabilities	97,669
Other Net Income	-10,063
Other Revenues	0
Property and Equipment	2,004
Research and Development	20,593
Selling, General and Administrative Expense	12,773

Output Variable	Value in 1000 USD
Assets	52,456
Liabilities	109,972
Expenses	33,323
Revenues	0
Stockholders Equity	-57,516
Net Income	-43,386
Comprehensive Net Income	-43,386
BaseVar	102,907
ECR before LimitedLiability	-208%
Economic Capital Ratio	100%